Hematology News

Valoctocogene roxaparvovec conferred sustained bleeding control at 2 years among a cohort of men with severe hemophilia A, according to phase 3 study results published in The New England Journal of Medicine.

Etranacogene dezaparvovec conferred superior bleed control for adults with moderate or severe hemophilia B compared with standard factor IX prophylaxis, according to results of the phase 3 HOPE-B study.

Packed red blood cell transfusion improved survival among adults with acute respiratory distress syndrome on venovenous extracorporeal membrane oxygenation when using a hemoglobin threshold of less than 7 g/dL, according to study results.

Although gay, bisexual and other men who have sex with men can serve as volunteer unrelated stem cell donors for people in need of transplants, they have long faced exclusion from donation and represent a largely untapped donor pool.

Crovalimab provided disease control and proved noninferior to a current standard-of-care treatment for certain patients with paroxysmal nocturnal hemoglobinuria, according to the agent’s manufacturer.

Odds of several adverse pregnancy outcomes appeared strikingly similar between pregnant people with anemia and pregnant people with sickle cell disease, according to a study published in JAMA Network Open.

The FDA has approved Jesduvroq tablets for treatment of anemia in patients with chronic kidney disease who are on dialysis, according to a press release.

Evidence suggests that high-risk patients with pulmonary embolism can benefit from surgical management, according to a scientific statement issued by the American Heart Association.

In a scientific statement, the American Heart Association issued guidance on the epidemiology, diagnosis and management of cancer therapy-induced hypertension.

A year ago, American Red Cross declared the first-ever national blood crisis amid a surge in the omicron variant of COVID-19.